Clinical Trial Update: Iparomlimab/Tuvorlimab (QL1706) and Modified TPF Regimen for Induction Therapy in LANPC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial assessing the combination of QL1706 (Iparomlimab/Tuvorlimab) with a modified TPF induction regimen for locally advanced nasopharyngeal …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• 5-Fluorouracil (5-FU)
• CISPLATIN (cisplatin)
• DOCETAXEL (DOCETAXEL)
• QL1706 (Iparomlimab/Tuvorlimab) (QL1706)

Snippet

Sponsor: The First Affiliated Hospital of Xiamen University | Conditions: Locally Advanced Nasopharyngeal Carcinoma, Immunotherapy | Phase 2 | Status: RECRUITING